Patents by Inventor Swaroop Kumar V. S. Vakkalanka

Swaroop Kumar V. S. Vakkalanka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases
    Patent number: 10442783
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: October 15, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
  • NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
    Publication number: 20190248791
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Application
    Filed: October 23, 2018
    Publication date: August 15, 2019
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Kanthikiran V.S. Varanasi, Gayatri Swaroop Merikapudi, Swaroop Kumar V.S. Vakkalanka
  • NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL
    Publication number: 20190160046
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 30, 2019
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Gayatri S. Merikapudi, Swaroop Kumar V.S. Vakkalanka
  • Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
    Patent number: 10174034
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: January 8, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Kanthikiran V S Varansi, Gayatri Swaroop Merikapudi, Swaroop Kumar V. S. Vakkalanka
  • Selective PI3K delta inhibitors
    Patent number: 10072013
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: September 11, 2018
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Compounds as modulators of protein kinases
    Patent number: 9775841
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: October 3, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant Kashinath Bhavar
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20170204105
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Inventors: Swaroop Kumar V.S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Selective PI3K delta inhibitors
    Patent number: 9669033
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: June 6, 2017
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20170020881
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Swaroop Kumar V.S. VAKKALANKA, Meyyappan MUTHUPPALANIAPPAN, Dhanapalan NAGARATHNAM
  • Selective PI3K delta inhibitors
    Patent number: 9475818
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: October 25, 2016
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • NOVEL SELECTIVE PI3K DELTA INHIBITORS
    Publication number: 20150361083
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 17, 2015
    Inventors: Swaroop Kumar V.S. VAKKALANKA, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Bicyclic compounds as modulators of GPR-119
    Patent number: 9181214
    Abstract: The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 10, 2015
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop Kumar V. S. Vakkalanka, Srikant Viswanadha, Gayatri S. Merikapudi
  • NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER
    Publication number: 20150291588
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Application
    Filed: February 19, 2015
    Publication date: October 15, 2015
    Applicant: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Kanthikiran VS Varansi, Gayatri Swaroop Merikapudi, Swaroop Kumar V.S. Vakkalanka
  • Selective PI3K delta inhibitors
    Patent number: 9150579
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: October 6, 2015
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop Kumar V. S. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Substituted chromenes as kinase modulators
    Patent number: 9018375
    Abstract: The present invention provides PI3K protein kinase modulators of formula (I): wherein R, R1, R2, L1, Cy1, Cy2 and n are as described herein, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: April 28, 2015
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
  • Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
    Patent number: 8993612
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: March 31, 2015
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Kanthikiran V S Varanasi, Gayatri Swaroop Merikapudi, Swaroop Kumar V. S. Vakkalanka
  • Modulators of calcium release-activated calcium channel
    Patent number: 8921364
    Abstract: Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 30, 2014
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Gayatri Swaroop Merikapudi, Swaroop Kumar V. S. Vakkalanka
  • 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases
    Patent number: 8912331
    Abstract: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 16, 2014
    Assignees: Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt. Ltd.
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop Kumar V. S. Vakkalanka
  • NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS
    Publication number: 20140220050
    Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
    Type: Application
    Filed: February 4, 2014
    Publication date: August 7, 2014
    Applicants: Incozen Therapeutics Pvt. Ltd., Rhizen Pharmaceuticals SA
    Inventors: Meyyappan MUTHUPPALANIAPPAN, Prashant Kashinath Bhavar, Srikant Viswanadha, Swaroop Kumar V.S. Vakkalanka, Gayatri Swaroop Merikapudi
  • Immunomodulator and anti-inflammatory compounds
    Patent number: 8686048
    Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: April 1, 2014
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Meyyappan Muthuppalaniappan, Prashant K. Bhavar, Srikant Viswanadha, Swaroop Kumar V. S. Vakkalanka, Gayatri S. Merikapudi